tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Judah Frommer, 120 are a BUY (72.29%), 41 are a HOLD (24.7%), 5 are a SELL (3.01%).
Analyst Judah Frommer, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 55.95% that have a potential upside of 30.26% achieved within 199 days.
Judah Frommer’s has documented 319 price targets and ratings displayed on 32 stocks. The coverage is on Consumer Defensive, Consumer Cyclical, Healthcare sectors.
Most recent stock forecast was given on GLPG, Galapagos NV ADR at 14-Feb-2025.
Analyst best performing recommendations are on ACLX (ARCELLX).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 5/15/2023. The price target of $151 was fulfilled within 1 day with a profit of $6.19 (3.94%) receiving and performance score of 39.38.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$90
$22.45 (33.23%)
$85
10 days ago
(01-Apr-2025)
14/26 (53.85%)
$14.66 (19.46%)
468
Buy
$95
$27.45 (40.64%)
$100
14 days ago
(28-Mar-2025)
5/13 (38.46%)
$22.25 (30.58%)
659
Hold
$82
$14.45 (21.39%)
$75
15 days ago
(27-Mar-2025)
13/34 (38.24%)
$5.05 (6.56%)
73
Buy
$84
$16.45 (24.35%)
$76
15 days ago
(27-Mar-2025)
27/39 (69.23%)
$7.05 (9.16%)
139
Hold
$78
$10.45 (15.47%)
$82
15 days ago
(27-Mar-2025)
16/26 (61.54%)
$1.05 (1.36%)
292
Which stock is Judah Frommer is most bullish on?
Which stock is Judah Frommer is most reserved on?
What Year was the first public recommendation made by Judah Frommer?
